Tauriga Sciences Inc. (TAUG) 0.0164 $TAUG
Tauriga Sciences Inc. Receives Additional $150,000 USD Private Placement Tranche from Tokyo Based Dragoon Capital, Inc.
PR Newswire - Wed Dec 24, 6:30AM CST
Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that Tokyo, Japan based Dragoon Capital, Inc. ("Dragoon" has invested an additional $150,000 USD of private placement capital into Tauriga. This additional $150,000 USD tranche was invested at a price of $0.0125 per share (Restricted) and there were no warrants offered in conjunction with this financing. To this date, Dragoon has now invested a total of $500,000 USD of private placement capital into Tauriga. The Company plans to use this additional capital to increase production of its TopiCanna brand of topical medicinal cannabis cream and establish a marketing campaign. The Company continues to work diligently toward the completion of the definitive distribution agreement with Japanese distributor iFLOW, Inc. ("iFLOW" . In anticipation of such agreement, the Company has been developing a TopiCanna product specific for the Japanese marketplace that incorporates CBD (Cannabidiol) from the stem of the plant (to comply with the laws and regulations of Japan).
Tauriga Sciences Inc. CBD (Cannabidiol) Infused TopiCanna Products Have Been Officially Launched
ACCESSWIRE - Tue Dec 16, 11:01AM CST
Los Angeles, CA / ACCESSWIRE / December 16, 2014 / Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today launched its first proprietary topical medicinal cannabis cream branded as TopiCanna. TopiCanna contains cannabidiol (CBD) oil from non-GMO industrial hemp that is grown without pesticides, herbicides, or chemical fertilizers. The oil has been lab tested for quality and is natural, safe and legal in the United States and in Japan, where Tauriga has a recently announced MOU with Tokyo-based iFLOW Ltd. There are no psychoactive effects associated with the CBD oil. Tauriga previously announced on November 25, 2014 that the Company planned to launch its TopiCanna product line within the next 60 days. TopiCanna's launch occurred well within the projected timeline. Initially the TopiCanna Products be sold directly by Tauriga Sciences, Inc. (interested parties may email inquiries to info@taurigasciences.com). The Company plans to expand TopiCanna's sales and marketing efforts to include online sales and distribution agreements, both domestically and internationally.
Tauriga Sciences Inc. Launches its First Topical Medicinal Cannabis Cream Branded as TopiCanna
ACCESSWIRE - Mon Dec 15, 1:45PM CST
Los Angeles, CA / ACCESSWIRE / December 15, 2014 / Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today launched its first proprietary topical medicinal cannabis cream branded as TopiCanna. TopiCanna contains cannabidiol (CBD) oil from non-GMO industrial hemp that is grown without pesticides, herbicides, or chemical fertilizers. The oil has been lab tested for quality and is natural, safe and legal in the United States and in Japan, where Tauriga has a recently announced MOU with Tokyo-based iFLOW Ltd. There are no psychoactive effects associated with the CBD oil. Tauriga previously announced on November 25, 2014 that the Company planned to launch its TopiCanna product line within the next 60 days. TopiCanna's launch occurred well within the projected timeline. TopiCanna will initially be sold directly by Tauriga (interested parties may email inquiries to info@taurigasciences.com). The Company plans to expand TopiCanna's sales and marketing efforts to include online sales and distribution agreements, both domestically and internationally.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 68.08 (+1.82), FULL: 4.76 (-0.01)
Tauriga Sciences Inc. Progresses Towards Launch of Its Topical Medicinal Cannabis Creams Branded as Topicanna
GlobeNewswire - Tue Nov 25, 6:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today updated shareholders about the upcoming launch of its proprietary topical medicinal cannabis creams to be branded as Topicanna. Several steps remain until an official launch is practical, however management is working diligently to complete these important steps; such steps are crucial to both the long term success and viability of the product line. These steps include: qualifying and testing oil with high cannabidiol (CBD) content from licensed suppliers, selecting the oil and scaling up the manufacturing process. The Company is hopeful that it can successfully launch its Topicanna product line within the next 60 days.
Legal Marijuana Industry Could Exceed $30Billion for 2020 as Additional States Approve Legalization - Company Adds Prominent Hollywood Personalities to Advisory Board
PR Newswire - Thu Nov 13, 7:45AM CST
According to Green Wave Advisors, the Legal Marijuana Industry is forecasted to reach $20 Billion to more than $30 Billion dependent upon the number of future states that approve legalization. Companies in focus today are: OSL Holdings, Inc. (OTC: OSLH), Tauriga Sciences, Inc. (OTC: TAUG), Terra Tech Corp. (OTC: TRTC), Hemp, Inc. (OTC: HEMP) and Surna Inc. (OTC: SRNA)
Medical Marijuana Clinical Trials Creating New Opportunities for Producing Therapeutic Medicines for Future FDA & INVIMA Applications
PR Newswire - Wed Nov 05, 7:45AM CST
Cannabis industry forecasts billions in revenue as United States moves towards legalization and MMJ Companies focus on new plans, joint ventures and development of innovative Marijuana products. Companies in Focus Today are: New Colombia Resources, Inc. (OTCQB: NEWC), Neutra Corp. (OTC: NTRR), Creative Edge Nutrition, Inc. (OTC: FITX), Tauriga Sciences, Inc. (OTC: TAUG) and Cannabis Science, Inc. (OTC: CBIS).
Tauriga Sciences Inc. Signs MOU to Distribute and Sell Natural Wellness Products Throughout Asia
GlobeNewswire - Tue Nov 04, 9:01AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that it has signed a non-binding MOU with Japan-based iFlow, Ltd. ("iFlow" to distribute and sell three new Tauriga-branded natural wellness products to the Japan, Taiwan and Hong Kong regions (the "Territory" . iFlow is an innovative and entrepreneurial Asian marketing and distribution company with motivational products in health, lifestyle, education, business and finance. If a definitive agreement is reached, the partnership between the companies would enable Tauriga to reach Asian customers with an interest in natural healing. The intent of the parties is for the initial focus of the partnership to be on two different formulations of Tauriga's proprietary TopiCanna topical cannabis cream and on Tauriga's CannaCaviar brand of small soft gel supplements. In compliance with Japanese medical marijuana law, all three products would use oil that has been extracted from the stalk of the cannabis plant and that is higher in CBD (cannabidiol) and low in THC, hence providing wellness and healing properties without psychoactive effects. If the initial phase of the proposed partnership is successful in establishing the Tauriga natural wellness brand in the Territory, the two companies plan to extend the agreement to include additional Tauriga products, such as Tauriga's new line of natural dietary supplements.
Small-Cap Marijuana Stocks to Watch This Week
ACCESSWIRE - Thu Oct 30, 10:49AM CDT
Coral Gables, FL / ACCESSWIRE / October 30, 2014 / Medbox, Inc. (OTCQB: MDBX) announced the addition of Tim Morrissey to lead Medbox's wholly owned subsidiary, Vaporfection International, Inc., as Director and Vice-President. Mr. Morrissey is the founder and Chief Executive Officer of Head Choice Inc., which is involved in many facets of the vaporization industry including consultation, manufacturing, sales and distribution. Its brands include the Da Buddha vaporizer, the Silver Surfer vaporizer, the Journey 2 and Journey 3 and most recently the Pax by Ploom.
Tauriga Sciences Inc. Appoints Michael J. Brennan, M.D., Ph.D. to Its Board of Directors
GlobeNewswire - Thu Oct 30, 6:30AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced the appointment of Michael J. Brennan, M.D., Ph.D. to its Board of Directors. Dr. Michael Brennan was previously President and Chief Executive Officer of Gene Logic, a NASDAQ-listed company. During Dr. Brennan's time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion. Dr. Brennan has previous experience in the biopharmaceutical industry, where he has served as Vice President, Business Development for Boehringer Mannheim Therapeutics. Dr. Brennan brings operating experience, technical and industry knowledge, and a thorough understanding of the NASDAQ market to the Tauriga Board of Directors.
Tauriga Sciences Inc. Completely Free of Convertible Debt
GlobeNewswire - Wed Oct 15, 6:30AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company is completely free of convertible debt for the first time since the fiscal fourth quarter of 2012. With the recent completion of a $600,000 USD equity private placement, announced by the Company on October 9, 2014, Tauriga is confident it can remain free of convertible debt for the foreseeable future. The elimination of the Company's convertible debt has substantially strengthened its balance sheet. With its strong current cash position, the Company is excited about its future prospects and its ability to potentially execute its business plan.
Tauriga Sciences, Inc. Completes $600,000 USD Equity Private Placement With Select Institutional and Accredited Individual Investors
GlobeNewswire - Thu Oct 09, 9:10PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, has today announced the completion of a $600,000 USD equity private placement with select institutional and accredited individual investors. The pricing of this equity private placement was at $0.0125 per share and there were no warrants offered in conjunction with this financing. The shares issued pursuant to this private placement are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended.
Tauriga Sciences Inc. Wholly Owned Subsidiary Pilus Energy LLC Invited to Present and Participate at EPA Technology Innovation Showcase on December 2, 2014 in Cincinnati, Ohio
GlobeNewswire - Thu Oct 02, 6:11AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" was invited to participate at the EPA Technology Innovation Showcase ("the Showcase) on December 2, 2014 in Cincinnati, Ohio. The Showcase will be held at the EPA's Environmental Research Center and at the Kingsgate Marriott Conference Center (across the street from EPA) from 8:00 am to 5:00 pm on that day. Pilus Energy will present about its proprietary Electrogenic Bioreactor ("EBR" technology platform in the morning and then in the afternoon Pilus Energy's General Manager, Mr. Cody Harrison, will participate in a discussion panel.
Tauriga Sciences Inc. Restructures Honeywood Transaction and Establishes Licensing and Supply Agreement
GlobeNewswire - Fri Sep 26, 6:00AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced the restructuring of its acquisition of Honeywood LLC ("Honeywood" into a License and Supply Agreement which provides Tauriga access to the Doc Green's topical cannabis cream and future products. Importantly, this restructuring also results in the full redemption of the common stock shares that were a significant portion of the Honeywood consideration under the merger transaction, which would have provided Honeywood with 15.4% of Tauriga's non-diluted shares of common stock outstanding at the time of closing, an additional 2.6% of our common stock shares to one of Honeywood's financial advisors, as well as the opportunity for the Honeywood principals to collectively earn up to an additional aggregate equal to 10% of Tauriga's common stock outstanding (utilizing the same initial Closing Date). The restructured transaction is significantly less dilutive to Tauriga shareholders because it provides that none of the 18% total common stock consideration and the up to 10% of additional common stock in the form of earn-out shares be issued to Honeywood's principals.
Tauriga Sciences Inc. Subsidiary Pilus Energy LLC Receives Approval from the US EPA to Commence Scaled Up Pilot Test
GlobeNewswire - Tue Sep 16, 12:44PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that on September 8, 2014, through its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" , received final approval for its Health and Safety Plan ("H & S Plan" . The approval was granted by the United States Environmental Protection Agency ("EPA" and the project subcontractor Chicago Bridge & Iron (NYSE:CBI) ("CB & I" , which operates the EPA's Test & Evaluation ("T & E" Facility where the next phase of the commercial pilot will take place. This final approval, along with the already approved Quality Assurance Project Plan ("QA Plan" , will enable the Company to commence development scale pilot testing at the EPA T& E Facility. The facility is co-located with the Metropolitan Sewer District of Great Cincinnati's ("MSDGC" largest wastewater treatment plant, on the Mill Creek site, which flows directly into the Ohio river.
CBI: 41.94 (-0.17)
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Tauriga Sciences, Inc.
GlobeNewswire - Tue Sep 16, 10:22AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview (EIO) on Tauriga Sciences, Inc. (TAUG-OTC). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
Tauriga Sciences Inc. Executes Investment Banking Agreement With Tokyo, Japan Based Dragoon Capital Inc.
GlobeNewswire - Mon Aug 25, 7:30AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that it has entered into an investment banking agreement with Tokyo, Japan based investment banking firm Dragoon Capital, Inc. ("Dragoon" . Through this investment banking agreement, Dragoon has agreed on a best efforts basis to secure the Company a private placement equity capital financing from its extensive base of both Japanese institutional and accredited individual investors. The proceeds from this private placement, if and when complete, should enable the Company to expand its medicinal cannabis and complementary natural wellness businesses as well as provide Pilus Energy with capital as it advances its pilot test program with the Metropolitan Sewer District of Greater Cincinnati ("MSDGC" and the EPA T&E department (Environmental Protection Agency's Testing & Evaluation department).
Tauriga Sciences Inc. to Present at Marijuana for Medical Professionals Conference on September 9 in Denver, Colorado
GlobeNewswire - Mon Aug 18, 6:26AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company's Chief Medical Officer, Lawrence A. May, M.D., F.A.C.P., will make a presentation on Tuesday, September 9th, 2014 at 12:15 PM at Marijuana for Medical Professionals Conference being held at the Sherman St Event Center in Denver, CO.
Tauriga Sciences Inc. Subsidiary Honeywood LLC's Berkeley, California Based Headquarters and Production Facility Now Operational
GlobeNewswire - Wed Aug 06, 6:50AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, is pleased to announce that its wholly owned subsidiary Honeywood LLC ("Honeywood" has successfully transitioned into its new Berkeley, California based headquarters and production facility. This new Honeywood headquarters complex includes: corporate offices for administrative activities, a substantially improved production facility, and laboratory space for research and development ("R & D" activities. Additionally Honeywood has moved its CO2 extraction machine into this new facility and is gearing up for another production run in the near future. In addition to its Doc Green's topical cannabis cream, which is already available in dispensaries in California, Honeywood has developed Vapura, a soon-to-be-launched medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor.
Tauriga Sciences Inc. Receives Additional $150,000 USD Private Placement Tranche from Tokyo Based Dragoon Capital, Inc.
PR Newswire - Wed Dec 24, 6:30AM CST
Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that Tokyo, Japan based Dragoon Capital, Inc. ("Dragoon" has invested an additional $150,000 USD of private placement capital into Tauriga. This additional $150,000 USD tranche was invested at a price of $0.0125 per share (Restricted) and there were no warrants offered in conjunction with this financing. To this date, Dragoon has now invested a total of $500,000 USD of private placement capital into Tauriga. The Company plans to use this additional capital to increase production of its TopiCanna brand of topical medicinal cannabis cream and establish a marketing campaign. The Company continues to work diligently toward the completion of the definitive distribution agreement with Japanese distributor iFLOW, Inc. ("iFLOW" . In anticipation of such agreement, the Company has been developing a TopiCanna product specific for the Japanese marketplace that incorporates CBD (Cannabidiol) from the stem of the plant (to comply with the laws and regulations of Japan). Tauriga Sciences Inc. CBD (Cannabidiol) Infused TopiCanna Products Have Been Officially Launched
ACCESSWIRE - Tue Dec 16, 11:01AM CST
Los Angeles, CA / ACCESSWIRE / December 16, 2014 / Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today launched its first proprietary topical medicinal cannabis cream branded as TopiCanna. TopiCanna contains cannabidiol (CBD) oil from non-GMO industrial hemp that is grown without pesticides, herbicides, or chemical fertilizers. The oil has been lab tested for quality and is natural, safe and legal in the United States and in Japan, where Tauriga has a recently announced MOU with Tokyo-based iFLOW Ltd. There are no psychoactive effects associated with the CBD oil. Tauriga previously announced on November 25, 2014 that the Company planned to launch its TopiCanna product line within the next 60 days. TopiCanna's launch occurred well within the projected timeline. Initially the TopiCanna Products be sold directly by Tauriga Sciences, Inc. (interested parties may email inquiries to info@taurigasciences.com). The Company plans to expand TopiCanna's sales and marketing efforts to include online sales and distribution agreements, both domestically and internationally. Tauriga Sciences Inc. Launches its First Topical Medicinal Cannabis Cream Branded as TopiCanna
ACCESSWIRE - Mon Dec 15, 1:45PM CST
Los Angeles, CA / ACCESSWIRE / December 15, 2014 / Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today launched its first proprietary topical medicinal cannabis cream branded as TopiCanna. TopiCanna contains cannabidiol (CBD) oil from non-GMO industrial hemp that is grown without pesticides, herbicides, or chemical fertilizers. The oil has been lab tested for quality and is natural, safe and legal in the United States and in Japan, where Tauriga has a recently announced MOU with Tokyo-based iFLOW Ltd. There are no psychoactive effects associated with the CBD oil. Tauriga previously announced on November 25, 2014 that the Company planned to launch its TopiCanna product line within the next 60 days. TopiCanna's launch occurred well within the projected timeline. TopiCanna will initially be sold directly by Tauriga (interested parties may email inquiries to info@taurigasciences.com). The Company plans to expand TopiCanna's sales and marketing efforts to include online sales and distribution agreements, both domestically and internationally. American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 68.08 (+1.82), FULL: 4.76 (-0.01)
Tauriga Sciences Inc. Progresses Towards Launch of Its Topical Medicinal Cannabis Creams Branded as Topicanna
GlobeNewswire - Tue Nov 25, 6:00AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today updated shareholders about the upcoming launch of its proprietary topical medicinal cannabis creams to be branded as Topicanna. Several steps remain until an official launch is practical, however management is working diligently to complete these important steps; such steps are crucial to both the long term success and viability of the product line. These steps include: qualifying and testing oil with high cannabidiol (CBD) content from licensed suppliers, selecting the oil and scaling up the manufacturing process. The Company is hopeful that it can successfully launch its Topicanna product line within the next 60 days. Legal Marijuana Industry Could Exceed $30Billion for 2020 as Additional States Approve Legalization - Company Adds Prominent Hollywood Personalities to Advisory Board
PR Newswire - Thu Nov 13, 7:45AM CST
According to Green Wave Advisors, the Legal Marijuana Industry is forecasted to reach $20 Billion to more than $30 Billion dependent upon the number of future states that approve legalization. Companies in focus today are: OSL Holdings, Inc. (OTC: OSLH), Tauriga Sciences, Inc. (OTC: TAUG), Terra Tech Corp. (OTC: TRTC), Hemp, Inc. (OTC: HEMP) and Surna Inc. (OTC: SRNA)
Medical Marijuana Clinical Trials Creating New Opportunities for Producing Therapeutic Medicines for Future FDA & INVIMA Applications
PR Newswire - Wed Nov 05, 7:45AM CST
Cannabis industry forecasts billions in revenue as United States moves towards legalization and MMJ Companies focus on new plans, joint ventures and development of innovative Marijuana products. Companies in Focus Today are: New Colombia Resources, Inc. (OTCQB: NEWC), Neutra Corp. (OTC: NTRR), Creative Edge Nutrition, Inc. (OTC: FITX), Tauriga Sciences, Inc. (OTC: TAUG) and Cannabis Science, Inc. (OTC: CBIS).
Tauriga Sciences Inc. Signs MOU to Distribute and Sell Natural Wellness Products Throughout Asia
GlobeNewswire - Tue Nov 04, 9:01AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that it has signed a non-binding MOU with Japan-based iFlow, Ltd. ("iFlow" to distribute and sell three new Tauriga-branded natural wellness products to the Japan, Taiwan and Hong Kong regions (the "Territory" . iFlow is an innovative and entrepreneurial Asian marketing and distribution company with motivational products in health, lifestyle, education, business and finance. If a definitive agreement is reached, the partnership between the companies would enable Tauriga to reach Asian customers with an interest in natural healing. The intent of the parties is for the initial focus of the partnership to be on two different formulations of Tauriga's proprietary TopiCanna topical cannabis cream and on Tauriga's CannaCaviar brand of small soft gel supplements. In compliance with Japanese medical marijuana law, all three products would use oil that has been extracted from the stalk of the cannabis plant and that is higher in CBD (cannabidiol) and low in THC, hence providing wellness and healing properties without psychoactive effects. If the initial phase of the proposed partnership is successful in establishing the Tauriga natural wellness brand in the Territory, the two companies plan to extend the agreement to include additional Tauriga products, such as Tauriga's new line of natural dietary supplements. Small-Cap Marijuana Stocks to Watch This Week
ACCESSWIRE - Thu Oct 30, 10:49AM CDT
Coral Gables, FL / ACCESSWIRE / October 30, 2014 / Medbox, Inc. (OTCQB: MDBX) announced the addition of Tim Morrissey to lead Medbox's wholly owned subsidiary, Vaporfection International, Inc., as Director and Vice-President. Mr. Morrissey is the founder and Chief Executive Officer of Head Choice Inc., which is involved in many facets of the vaporization industry including consultation, manufacturing, sales and distribution. Its brands include the Da Buddha vaporizer, the Silver Surfer vaporizer, the Journey 2 and Journey 3 and most recently the Pax by Ploom.
Tauriga Sciences Inc. Appoints Michael J. Brennan, M.D., Ph.D. to Its Board of Directors
GlobeNewswire - Thu Oct 30, 6:30AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced the appointment of Michael J. Brennan, M.D., Ph.D. to its Board of Directors. Dr. Michael Brennan was previously President and Chief Executive Officer of Gene Logic, a NASDAQ-listed company. During Dr. Brennan's time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion. Dr. Brennan has previous experience in the biopharmaceutical industry, where he has served as Vice President, Business Development for Boehringer Mannheim Therapeutics. Dr. Brennan brings operating experience, technical and industry knowledge, and a thorough understanding of the NASDAQ market to the Tauriga Board of Directors. Tauriga Sciences Inc. Completely Free of Convertible Debt
GlobeNewswire - Wed Oct 15, 6:30AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company is completely free of convertible debt for the first time since the fiscal fourth quarter of 2012. With the recent completion of a $600,000 USD equity private placement, announced by the Company on October 9, 2014, Tauriga is confident it can remain free of convertible debt for the foreseeable future. The elimination of the Company's convertible debt has substantially strengthened its balance sheet. With its strong current cash position, the Company is excited about its future prospects and its ability to potentially execute its business plan. Tauriga Sciences, Inc. Completes $600,000 USD Equity Private Placement With Select Institutional and Accredited Individual Investors
GlobeNewswire - Thu Oct 09, 9:10PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, has today announced the completion of a $600,000 USD equity private placement with select institutional and accredited individual investors. The pricing of this equity private placement was at $0.0125 per share and there were no warrants offered in conjunction with this financing. The shares issued pursuant to this private placement are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended.
Tauriga Sciences Inc. Wholly Owned Subsidiary Pilus Energy LLC Invited to Present and Participate at EPA Technology Innovation Showcase on December 2, 2014 in Cincinnati, Ohio
GlobeNewswire - Thu Oct 02, 6:11AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" was invited to participate at the EPA Technology Innovation Showcase ("the Showcase) on December 2, 2014 in Cincinnati, Ohio. The Showcase will be held at the EPA's Environmental Research Center and at the Kingsgate Marriott Conference Center (across the street from EPA) from 8:00 am to 5:00 pm on that day. Pilus Energy will present about its proprietary Electrogenic Bioreactor ("EBR" technology platform in the morning and then in the afternoon Pilus Energy's General Manager, Mr. Cody Harrison, will participate in a discussion panel. Tauriga Sciences Inc. Restructures Honeywood Transaction and Establishes Licensing and Supply Agreement
GlobeNewswire - Fri Sep 26, 6:00AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced the restructuring of its acquisition of Honeywood LLC ("Honeywood" into a License and Supply Agreement which provides Tauriga access to the Doc Green's topical cannabis cream and future products. Importantly, this restructuring also results in the full redemption of the common stock shares that were a significant portion of the Honeywood consideration under the merger transaction, which would have provided Honeywood with 15.4% of Tauriga's non-diluted shares of common stock outstanding at the time of closing, an additional 2.6% of our common stock shares to one of Honeywood's financial advisors, as well as the opportunity for the Honeywood principals to collectively earn up to an additional aggregate equal to 10% of Tauriga's common stock outstanding (utilizing the same initial Closing Date). The restructured transaction is significantly less dilutive to Tauriga shareholders because it provides that none of the 18% total common stock consideration and the up to 10% of additional common stock in the form of earn-out shares be issued to Honeywood's principals. Tauriga Sciences Inc. Subsidiary Pilus Energy LLC Receives Approval from the US EPA to Commence Scaled Up Pilot Test
GlobeNewswire - Tue Sep 16, 12:44PM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that on September 8, 2014, through its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" , received final approval for its Health and Safety Plan ("H & S Plan" . The approval was granted by the United States Environmental Protection Agency ("EPA" and the project subcontractor Chicago Bridge & Iron (NYSE:CBI) ("CB & I" , which operates the EPA's Test & Evaluation ("T & E" Facility where the next phase of the commercial pilot will take place. This final approval, along with the already approved Quality Assurance Project Plan ("QA Plan" , will enable the Company to commence development scale pilot testing at the EPA T& E Facility. The facility is co-located with the Metropolitan Sewer District of Great Cincinnati's ("MSDGC" largest wastewater treatment plant, on the Mill Creek site, which flows directly into the Ohio river. CBI: 41.94 (-0.17)
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Tauriga Sciences, Inc.
GlobeNewswire - Tue Sep 16, 10:22AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview (EIO) on Tauriga Sciences, Inc. (TAUG-OTC). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
Tauriga Sciences Inc. Executes Investment Banking Agreement With Tokyo, Japan Based Dragoon Capital Inc.
GlobeNewswire - Mon Aug 25, 7:30AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that it has entered into an investment banking agreement with Tokyo, Japan based investment banking firm Dragoon Capital, Inc. ("Dragoon" . Through this investment banking agreement, Dragoon has agreed on a best efforts basis to secure the Company a private placement equity capital financing from its extensive base of both Japanese institutional and accredited individual investors. The proceeds from this private placement, if and when complete, should enable the Company to expand its medicinal cannabis and complementary natural wellness businesses as well as provide Pilus Energy with capital as it advances its pilot test program with the Metropolitan Sewer District of Greater Cincinnati ("MSDGC" and the EPA T&E department (Environmental Protection Agency's Testing & Evaluation department). Tauriga Sciences Inc. to Present at Marijuana for Medical Professionals Conference on September 9 in Denver, Colorado
GlobeNewswire - Mon Aug 18, 6:26AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that the Company's Chief Medical Officer, Lawrence A. May, M.D., F.A.C.P., will make a presentation on Tuesday, September 9th, 2014 at 12:15 PM at Marijuana for Medical Professionals Conference being held at the Sherman St Event Center in Denver, CO. Tauriga Sciences Inc. Subsidiary Honeywood LLC's Berkeley, California Based Headquarters and Production Facility Now Operational
GlobeNewswire - Wed Aug 06, 6:50AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, is pleased to announce that its wholly owned subsidiary Honeywood LLC ("Honeywood" has successfully transitioned into its new Berkeley, California based headquarters and production facility. This new Honeywood headquarters complex includes: corporate offices for administrative activities, a substantially improved production facility, and laboratory space for research and development ("R & D" activities. Additionally Honeywood has moved its CO2 extraction machine into this new facility and is gearing up for another production run in the near future. In addition to its Doc Green's topical cannabis cream, which is already available in dispensaries in California, Honeywood has developed Vapura, a soon-to-be-launched medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor. 
